HLA-B*57:01/Carbamazepine-10,11-Epoxide Association Triggers Upregulation of the NFκB and JAK/STAT Pathways DOI Creative Commons
Funmilola Josephine Haukamp,

Zoe Maria Hartmann,

Andreas Pich

и другие.

Cells, Год журнала: 2023, Номер 12(5), С. 676 - 676

Опубликована: Фев. 21, 2023

Measure of drug-mediated immune reactions that are dependent on the patient's genotype determine individual medication protocols. Despite extensive clinical trials prior to license a specific drug, certain patient-specific cannot be reliably predicted. The need for acknowledgement actual proteomic state selected individuals under drug administration becomes obvious. well-established association between HLA molecules and drugs or their metabolites has been analyzed in recent years, yet polymorphic nature makes broad prediction unfeasible. Dependent genotype, carbamazepine (CBZ) hypersensitivities can cause diverse disease symptoms as maculopapular exanthema, reaction with eosinophilia systemic more severe diseases Stevens-Johnson-Syndrome toxic epidermal necrolysis. Not only HLA-B*15:02 HLA-A*31:01 but also HLA-B*57:01 CBZ could demonstrated. This study aimed illuminate mechanism HLA-B*57:01-mediated hypersensitivity by full proteome analysis. main metabolite EPX introduced drastic alterations induction inflammatory processes through upstream kinase ERBB2 upregulation NFκB JAK/STAT pathway implying pro-apoptotic, pro-necrotic shift cellular response. Anti-inflammatory pathways associated effector proteins were downregulated. disequilibrium pro- anti-inflammatory clearly explain fatal following administration.

Язык: Английский

Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A 15-year Regional Burn Center Experience DOI Creative Commons

Doha Obed,

Mustafa Salim,

Khaled Dastagir

и другие.

JPRAS Open, Год журнала: 2025, Номер 44, С. 83 - 92

Опубликована: Фев. 8, 2025

Язык: Английский

Процитировано

0
Systematic review, methodological appraisal, and recommendation mapping of clinical practice guidelines for managing patients with Stevens-Johnson syndrome and toxic epidermal necrolysis DOI Creative Commons
Mohammed A. AlShahwan, Hend Alotaibi, Abdulmajeed Alajlan

и другие.

Journal of Dermatological Treatment, Год журнала: 2025, Номер 36(1)

Опубликована: Фев. 26, 2025

Purpose The Appraisal of Guidelines for Research and Evaluation II Instrument (AGREE II) was developed to enhance the methodological rigor clinical practice guidelines (CPGs), aiming generate trustworthy recommendations various scenarios. Despite its importance, there exists a gap in quality CPGs pertaining Stevens–Johnson Syndrome Toxic Epidermal Necrolysis (SJS-TEN). aim study evaluate SJS-TEN shed light on areas enhancing guidelines' quality.

Язык: Английский

Процитировано

0
Clinical features of nivolumab-induced Stevens-Johnson syndrome/toxic epidermal necrolysis: retrospective analysis based on case reports DOI Creative Commons
Ronghui Li, Haibo Lei, Chunjiang Wang

и другие.

Frontiers in Immunology, Год журнала: 2025, Номер 16

Опубликована: Март 18, 2025

Stevens - Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a life-threatening adverse reaction to nivolumab. This study investigated the clinical features of nivolumab induced SJS/TEN provide evidence for diagnosis and treatment. Relevant articles on published before December 31, 2024 were collected by searching database, then extracting data summary analysis. Thirty-one patients enrolled with median age 65 years (range 43, 86). appear at 5.5 weeks (range, 0.9 108). Bullae/blisters (64.5%), erythema (54.8%), skin rash detachment (29.0%) pain main symptoms. Skin biopsy showed necrosis (41.9%), keratinocytic (38.7%), interface dermatitis inflammatory cell infiltration (45.2%). After stopping receiving treatment, 74.2% had improvement in symptoms, 22.6% died TEN. As rare immune-related event nivolumab, should be closely monitored during Nivolumab has long incubation period, serious symptoms poor prognosis.

Язык: Английский

Процитировано

0
Latin American guidelines for the diagnosis and treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis DOI Creative Commons

Andrea Dionelly Murillo-Casas,

Ricardo Zwiener, Pedro Giavina‐Bianchi

и другие.

World Allergy Organization Journal, Год журнала: 2025, Номер 18(4), С. 101046 - 101046

Опубликована: Март 28, 2025

Язык: Английский

Процитировано

0
Non-steroidal anti-inflammatory drugs induced toxic epidermal necrolysis DOI Open Access

Lahari Samudrala,

Bhanu Pratap Singh,

Rajya Laxmi Papasani

и другие.

International Journal of Community Medicine and Public Health, Год журнала: 2025, Номер 12(4), С. 1900 - 1903

Опубликована: Март 28, 2025

This case report presents a 48-year-old woman with history of chronic kidney disease who experienced toxic epidermal necrolysis (TEN), also known as Lyell's syndrome, an uncommon and severe adverse drug reaction. The TEN was attributed to the use non-steroidal anti-inflammatory drugs (NSAIDs). Cutaneous involvement exceeded 80% body surface area (BSA), encompassing ocular, oral, nasal mucosa, well trunk, bilateral limbs, genitalia. Treatment commenced aggressive fluid resuscitation, administration cyclosporine, meticulous dermal care. patient ultimately discharged following approximately one month intensive therapy.

Язык: Английский

Процитировано

0
Potential drugs associated with toxic epidermal necrolysis: a disproportionality analysis based on the FAERS database (2004–2024) DOI
Xiaojian Li,

Zhangren Yan,

Shiyu Chen

и другие.

Archives of Dermatological Research, Год журнала: 2025, Номер 317(1)

Опубликована: Март 29, 2025

Язык: Английский

Процитировано

0
Toxic Epidermal Necrolysis in a Critically Ill African American Woman: A Case Report Written With ChatGPT Assistance DOI Open Access

Rebekah Lantz

Cureus, Год журнала: 2023, Номер unknown

Опубликована: Март 3, 2023

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening spectrum diseases in which a medication triggers mucocutaneous reaction associated with severe necrosis loss of integrity. The disease has high mortality rate that can be assessed by dermatology scoring scales based on an affected total body surface area (TBSA). Sloughing <10% TBSA is considered SJS, 10%. >30% termed TEN, increased 25% to 35%. We present case management TEN involved critically ill African American woman. Identification the offending agent was difficult due complicated exposure throughout her multi-facility care management. This conveys importance close monitoring patient during clinical course involving SJS-/TEN-inducing drugs. also discuss potential risks for SJS/TEN population genetic or epigenetic predispositions skin conditions. report contributes increasing color representation current literature. Additionally, we use Chat Generative Pre-trained Transformer (ChatGPT, OpenAI LP, Inc., San Francisco, CA, USA) list its benefits errors.

Язык: Английский

Процитировано

10
Biologic TNF-α Inhibitors for Stevens–Johnson Syndrome, Toxic Epidermal Necrolysis, and TEN-SJS Overlap: A Study-Level and Patient-Level Meta-Analysis DOI Creative Commons
Jiali Cao, Xuan Zhang,

Xinzhu Xing

и другие.

Dermatology and Therapy, Год журнала: 2023, Номер 13(6), С. 1305 - 1327

Опубликована: Май 13, 2023

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe cutaneous adverse reactions with high morbidity mortality not clearly established treatment protocol. This meta-analysis aimed to evaluate the efficacy safety of three biologic TNF-α inhibitors (infliximab, etanercept, adalimumab) in SJS, SJS-TEN overlap, TEN.Electronic databases were searched for original studies containing human participants diagnosed SJS/TEN treated inhibitors. Individual patient data collected summarized provide a comprehensive overview on therapeutic different TEN, respectively. Meta-analyses aggregated study conducted using random-effects model.Overall, 55 125 sets individual included. Infliximab was used treat 3 patients overlap 28 actual rate 33.3% 17%, Etanercept administered 17 9 64 reported be 0%, 12.5%, For no significant difference found time reepithelialization, hospitalization time, comparing etanercept infliximab. More sequelae receiving infliximab than (39.3% versus 6.4%). Adalimumab four 25%. revealed significantly shortened compared non-etanercept groups [weighted mean differences (WMD) -5.30; 95% confidence interval (CI) -8.65 -1.96]. associated survival benefit when treatment, however, analysis statistically (odds ratio 0.55; CI 0.23-1.33).On basis current findings, is currently most promising therapy SJS/TEN. Further evaluation prospective required confirm its safety.

Язык: Английский

Процитировано

10
Multidisciplinary Treatment in Toxic Epidermal Necrolysis DOI Open Access
Agnieszka Surowiecka, Wioletta Barańska‐Rybak, Jerzy Strużyna

и другие.

International Journal of Environmental Research and Public Health, Год журнала: 2023, Номер 20(3), С. 2217 - 2217

Опубликована: Янв. 26, 2023

Toxic epidermal necrolysis, Leyll's syndrome (TEN), is a rare mucocutaneous blistering disease burdened with high mortality rates. The diagnosis of TEN based on clinical symptoms and histopathological findings. In approximately 90% cases, it severe adverse reaction to drugs. TEN, not only the skin affected, but also mucosa organs' epithelium. There are no unequivocal recommendations in regard systemic topical treatment patients. aim this paper review available literature propose unified protocols be discussed. Early management multidisciplinary necessary improve patients' outcome. Treatment patients suspicions should initiated early drug withdrawal. patients, like burns, require intensive care management. Each patient provided adequate fluid resuscitation, respiratory support, nutritional treatment, pain control, infection prophylaxis, anticoagulant therapy, gastric ulcer prophylaxis. key local use nonadherent dressings that do damage epidermis during change. purification blood stream from causative agent. most efficient way clarify serum combination plasmapheresis IVIG. Immunomodulatory therapy can reduce five times comparison immunosuppression or lack full protocol.

Язык: Английский

Процитировано

7
Adalimumab for Sintilimab-Induced Toxic Epidermal Necrolysis in a Patient with Metastatic Gastric Malignancy: A Case Report and Literature Review DOI Creative Commons
Li Zhang,

Zhongxiao Wu

Clinical Cosmetic and Investigational Dermatology, Год журнала: 2023, Номер Volume 16, С. 457 - 461

Опубликована: Фев. 1, 2023

Sintilimab is a recombinant fully human anti-programmed cell death protein 1 (PD-1) monoclonal antibody that blocks the interaction of PD-1 with its ligand. It was approved to use in patients gastric malignancy. Toxic epidermal necrolysis (TEN) rare, life-threatening cutaneous drug reaction. Here, we report 70-year-old female patient malignancy who developed severe TEN 10 days after initiation sintilimab. The did not respond systemic corticosteroids and intravenous immunoglobulin therapies but improved subcutaneous injection adalimumab (40 mg) directed against antitumor necrosis factor-α. Her rashes rapidly resolved within 24 hr. By seventh day, bullae had scabbed most skin lesions subsided. showed no sign organ dysfunction. This first reported case immune checkpoint inhibitor-induced successfully treated adalimumab.

Язык: Английский

Процитировано

7